[go: up one dir, main page]

DK1345598T3 - Anvendelsen af rosiglitazon til behandling af psykiatriske lidelser - Google Patents

Anvendelsen af rosiglitazon til behandling af psykiatriske lidelser

Info

Publication number
DK1345598T3
DK1345598T3 DK01271216T DK01271216T DK1345598T3 DK 1345598 T3 DK1345598 T3 DK 1345598T3 DK 01271216 T DK01271216 T DK 01271216T DK 01271216 T DK01271216 T DK 01271216T DK 1345598 T3 DK1345598 T3 DK 1345598T3
Authority
DK
Denmark
Prior art keywords
rosiglitazone
treatment
psychiatric disorders
psychiatric
disorders
Prior art date
Application number
DK01271216T
Other languages
Danish (da)
English (en)
Inventor
Gayle Chapman
Mary Vinson
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DK1345598T3 publication Critical patent/DK1345598T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK01271216T 2000-12-18 2001-12-12 Anvendelsen af rosiglitazon til behandling af psykiatriske lidelser DK1345598T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0030845.2A GB0030845D0 (en) 2000-12-18 2000-12-18 Novel treatment
PCT/GB2001/005488 WO2002049626A2 (en) 2000-12-18 2001-12-12 The use of ppar-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired pasticity

Publications (1)

Publication Number Publication Date
DK1345598T3 true DK1345598T3 (da) 2008-02-04

Family

ID=9905313

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01271216T DK1345598T3 (da) 2000-12-18 2001-12-12 Anvendelsen af rosiglitazon til behandling af psykiatriske lidelser

Country Status (15)

Country Link
US (2) US20040077525A1 (es)
EP (2) EP1911446A3 (es)
JP (2) JP2004518652A (es)
AR (1) AR032001A1 (es)
AT (1) ATE372118T1 (es)
AU (1) AU2002222180A1 (es)
DE (1) DE60130365T2 (es)
DK (1) DK1345598T3 (es)
ES (1) ES2292529T3 (es)
GB (1) GB0030845D0 (es)
PE (1) PE20020601A1 (es)
PT (1) PT1345598E (es)
TW (1) TWI298998B (es)
UY (1) UY27071A1 (es)
WO (1) WO2002049626A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US20050004179A1 (en) * 2003-05-22 2005-01-06 Pedersen Ward A. Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
AU2003254146A1 (en) * 2003-07-24 2005-03-07 Case Western Reserve University Methods for the treatment of parkinson's disease
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
RU2445957C2 (ru) * 2006-03-16 2012-03-27 Метаболик Солюшнз Девелопмент Компани Аналоги тиазолидиндиона
CA2663347A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. Ppar mediated modulation of neurogenesis
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
ES2830073T3 (es) 2007-04-11 2021-06-02 Omeros Corp Composiciones y métodos para la profilaxis y el tratamiento de adicciones
KR101767273B1 (ko) 2009-03-11 2017-08-10 오메로스 코포레이션 중독의 예방 및 치료용 조성물 및 방법
EP2766018A4 (en) * 2011-10-13 2015-02-25 Univ Case Western Reserve RXR AGONIST COMPOUNDS AND METHOD THEREFOR
MX2015007479A (es) * 2012-12-11 2015-09-04 Metabolic Solutions Dev Co Llc Tiazolidindionas ahorradoras de receptores activados proliferadores de peroxisoma (ppar) y combinaciones para el tratamiento de enfermedades neurodegenerativas.
US20150359849A1 (en) * 2013-01-31 2015-12-17 President And Fellows Of Harvard College Methods of increasing neuronal connectivity and/or treating a neurodegenerative condition
WO2016071727A1 (en) 2014-11-04 2016-05-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
US12310967B2 (en) 2017-12-21 2025-05-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
US12274703B2 (en) 2017-12-21 2025-04-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
GB201805554D0 (en) * 2018-04-04 2018-05-16 Wren Therapeutics Therapy for protein misfolding disease
US20210228558A1 (en) * 2018-06-06 2021-07-29 Minoryx Therapeutics S.L. Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
JP4473355B2 (ja) * 1997-11-19 2010-06-02 武田薬品工業株式会社 アポトーシス抑制剤
EP1047423B1 (en) * 1997-11-19 2006-05-10 Takeda Pharmaceutical Company Limited Novel apoptosis inhibitors
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
DE69942672D1 (de) * 1998-12-17 2010-09-23 Mindset Biopharmaceuticals Usa Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns
JP2000273040A (ja) * 1999-01-19 2000-10-03 Sankyo Co Ltd トログリタゾンを含有するアポトーシス抑制剤
US6204288B1 (en) * 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
GB9908647D0 (en) * 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
AU7995300A (en) * 1999-10-05 2001-05-10 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives

Also Published As

Publication number Publication date
ES2292529T3 (es) 2008-03-16
ATE372118T1 (de) 2007-09-15
JP2004518652A (ja) 2004-06-24
PT1345598E (pt) 2007-12-06
AR032001A1 (es) 2003-10-22
UY27071A1 (es) 2002-07-31
EP1911446A2 (en) 2008-04-16
US20070238757A1 (en) 2007-10-11
EP1345598A2 (en) 2003-09-24
DE60130365D1 (de) 2007-10-18
EP1345598B1 (en) 2007-09-05
TWI298998B (en) 2008-07-21
US20040077525A1 (en) 2004-04-22
EP1911446A3 (en) 2008-09-24
WO2002049626A3 (en) 2002-10-17
DE60130365T2 (de) 2008-05-29
WO2002049626A2 (en) 2002-06-27
AU2002222180A1 (en) 2002-07-01
GB0030845D0 (en) 2001-01-31
PE20020601A1 (es) 2002-09-22
JP2008260777A (ja) 2008-10-30

Similar Documents

Publication Publication Date Title
DK1345598T3 (da) Anvendelsen af rosiglitazon til behandling af psykiatriske lidelser
DK1343773T3 (da) Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
DK1047428T3 (da) Anvendelse af morpholinol til behandlingen af seksualforstyrrelser
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DK3167872T3 (da) Fremgangsmåder til behandling af inflammationsmedierede tilstande i øjet
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
DK1620437T3 (da) 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
DK1575597T3 (da) Anvendelse af rimexolon til behandling af öjentörhed
DK1562932T3 (da) 4 tetrazolyl-4-phenylpiperidinderivater til behandling af smerter
AR027945A1 (es) Uso de pramipexol en el tratamiento de transtornos de adiccion
DK1231920T3 (da) Anvendelse af epinastin til behandling af allergisk rhinitis/conjunctivitis
EE200200571A (et) Hüdroksüfenüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
DK1176964T3 (da) Brug af ET743 til behandling af cancer
DK2189162T3 (da) Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
NO20032122L (no) Forbedret behandling
DK1326628T3 (da) Kemokinmutanter til behandling af dissemineret sklerose
EE200200577A (et) Kinolinüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
EE200200511A (et) Hüdroksüfenüülpiperasinüülmetüülbensamiidi derivaadid valu raviks
DK1257278T3 (da) Anvendelse af mirtazapin til behandling af sövnforstyrrelser
NO20030978D0 (no) Behandling av diuresedysfunksjon
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
DK1468686T3 (da) S-methyl-dihydro-ziprasidon til behandling af psykiatriske lidelser
DK1461042T3 (da) Anvendelse af desoxypeganin til behandling af klinisk depression
NO20030717L (no) Forbindelser for behandling av avhengighetsforstyrrelser